Aptar Pharma’s innovative, preservative-free multidose Ophthalmic Squeeze Dispenser has been announced as the delivery device for Bausch+Lomb’s Levofree Multidose in France which has received approval by the French National Agency for Medicines and Health Products (ANSM).
Aptar Pharma has been working closely with Bausch+Lomb, one of the world’s leading Eye Care companies, to achieve this first ANSM approval of an Eye Care product with its preservative-free multidose device. This launch has further expanded the track record of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the delivery system of choice for preservative-free Eye Care formulations.
With more than 450 commercial references worldwide, Aptar Pharma’s Ophthalmic Squeeze Dispenser meets key industry needs for preservative-free multi-dose devices and is designed to comply with the regulatory requirements for eyecare products. The ergonomic intuitiveness of the squeezable container with a low actuation force contributes to the high levels of acceptance. The Eye Care delivery solution is the result of more than 10 years of development and experience in the delivery of preservative-free ophthalmic solutions, providing proven microbiological integrity for preservative-free Eye Care products.
“Our Ophthalmic Dispenser technology has been a great success for our customers,” explained Matthias Birkhoff, Vice President Business Development, Aptar Pharma. “Proven microbiological integrity based on Aptar Pharma’s challenging TSIT 2.0 test protocol, combined with a precise and reproducible drop ejection, allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the French ANSM with confidence.”
For full details, download our press release here.
